Our Science – Kreitman Website
Robert J. Kreitman, M.D.
| Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia - Relapsed Hairy Cell Leukemia, Multicenter Immunotherapy Non-Placebo Phase 3 Trial|
| Cladribine and Rituximab for Early Hairy Cell Leukemia - Trial using rituximab to prevent relapse in early hairy cell leukmeia|
| Study of Ibrutinib for Treatment of Relapsed Hairy Cell Leukemia - For patients with relapsed hairy cell leukemia (HCL), including HCL variant|
| Phase II trial of LMB-2 after fludarabine and cyclophosphamide for adult T-cell leukemia - For patients with adult T-cell leukemia to target the ATL cells, using FC chemotherapy to prevent antibodies and improve the chance for complete remission|
| Randomized trial of rituximab with either bendamustine or pentostatin for hairy cell leukemia - Patients who have had multiple prior treatments for HCL|
| LMB-2 to Treat Hairy Cell Leukemia - A non-chemotherapy option for patients with hairy cell leukemia who are not eligible for Moxetumomab Pasudotox|
| LMB trials at NIH - LMB trials at NIH, NCI|
| Moxetumomab Pasudotox Info - Information regarding the Phase 3 Pivotal trial of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia|
| Moxetumomab Pasudotox trial letter - Letter to physicans|
This page was last updated on 3/26/2014.